Supplementary Information for

**Epigenetic reactivation of LC3B induces melanoma cell death and predicts response to immunotherapy**

Gregory M. Kelly1,2, Fares Al-Ejeh1,†, Robert McCuaig1, Francesco Casciello1,4, Nabilah Ahmad Kamal1, Blake Ferguson1, Antonia L. Pritchard1, Sayed Ali3,5, Ines P. Silva6,7,8, James S. Wilmott6,7,8, Georgina V. Long6,7,8,9,10, Richard A. Scolyer6,7,8,9,11, Sudha Rao1, Nicholas K. Hayward1, Frank Gannon1 and Jason S. Lee1,2,4 \*.

Jason Lee

Email: Jason.Lee@qimrberghofer.edu.au

**This file includes:**

Supplementary Tables S1 to S7

**Supplementary Table S1. Melanoma cell lines used in this study including identified genetic alterations in important genes.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cell****Lines** | **Stage** | **Primary site** | **BRAF** | **NF1** | **CDKN2A** | **FGFR2** | **MC1R** | **Nras** | **p14ARF** | **PTEN** | **p53** |
| A04 | 4 | non-CSD | wt | wt | HD | A648T | V60L +/- | wt | HD | wt | wt |
| C092 | 3 | occult | wt | likely wt | wt | wt | wt | wt | n/a | wt | wt |
| C006 | 3 | non-CSD | wt | likely wt | n/a | n/a | wt | Q61L | wt | n/a | wt |
| C013 | 3 | non-CSD | wt | wt | wt | wt | R151C +/-D294H +/- | Q61L | wt | 380G>AGly127Glu | P278S |
| C008 | 3 | occult | wt | splice | wt | wt | wt | wt | n/a | wt | wt |
| D22 | 4 | n/a | wt | R440X | wt | R759stop;D530N | D294H -/- | wt | wt | wt | E287K |
| D05 | 4 | non-CSD | V600E | likely wt | LOH+[frameshift] | wt | R151C +/- | wt | wt | wt | wt |
| D14 | 4 | non-CSD | V600E | likely wt | LOH+P114L | wt | wt | wt | wt | HD | G266E |
| D20 | 4 | n/a | V600E | likely wt | wt | n/a | wt | wt | wt | HD | R248Q |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cell****Lines** | **Rb** | **TERT** **(% mutant)** | **MEK** | **BCL2L12** | **MAP3K9** | **FLRT2** | **HDAC7** | **HDAC9** | **ERBB4** | **MET** |
| A04 | wt | wt | wt | wt | wt | wt | wt | wt | wt | wt |
| C092 | wt | wt | wt | wt | wt | n/a | wt | wt | wt | T922I |
| C006 | wt | wt | wt | wt | wt | R486Q | n/a | n/a | n/a | n/a |
| C013 | R455X | 138CC>TT | wt | wt | wt | wt | wt | wt | wt | wt |
| C008 | n/a | -146C/T | wt | F17F | R160C | n/a | wt | E982A | R1067Q | E75KR242K |
| D22 | n/a | -124 C/T | P124L | wt | wt | E102K | n/a | n/a | n/a | n/a |
| D05 | wt | -124C/T | wt | F17F | P263L | wt | wt | wt | wt | wt |
| D14 | wt | -124 T/T | wt | wt | Y646C | wt | E892K | wt | wt | wt |
| D20 | n/a | -146 T/T | wt | wt | wt | wt | n/a | n/a | n/a | n/a |

**Supplementary Table S2. Antibodies used in this study.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Antibodies** | **Company** | **Species** | **Dilution** | **Catalog #** | **RRID** |
| **Westerns** |  |  |  |  |  |
| **Primaries** |  |  |  |  |  |
| G9a | Cell Signaling | Rabbit | 1:1000 | 3306S |  |
| LC3B | Abcam | Rabbit | 1:500 | ab48394 |  |
| P62 | Cell Signaling | Rabbit  | 1:1000 | 8025S |  |
| H3K9me2 | Abcam | Rabbit | 1:700 | ab1220 |  |
| Cleaved PARP | BD Biosciences | Mouse | 1:1000 | 552596 |  |
| Total H3 | Abcam | Rabbit | 1:1000 | ab1791 |  |
| Tubulin | Abcam | Rabbit | 1:5000 | ab6046 |  |
| **Secondaries** |  |  |  |  |  |
| Anti-rabbit HRP | Cell Signaling |  | 1:10000 | 7074S |  |
| Anti-mouse HRP | Cell Signaling |  | 1:10000 | 7076S | AB\_330924 |
| **ChIP** |  |  |  |  |  |
| G9a | Abcam | Rabbit |  | ab40542 | AB\_731483 |
| H3K9me2 | Abcam | Rabbit |  | ab1220 |  |
| RNA polymerase II | Abcam | Rabbit |  | ab817 |  |
| IgG control | Abcam | Rabbit |  | ab37415 |  |
| **IHC** |  |  |  |  |  |
| G9a | Abcam | Rabbit | 1:8000 | ab40542  |  |
| LC3B | Cell Signaling | Rabbit | 1:14000 | 3868S |  |
| SOX10 | Santa Cruz | Goat | 1:600 | sc-17342 | AB\_2195374 |
| PD-L1 | Abcam | Rabbit | 1:1000 | ab213480 | AB\_2773715 |
| CD8a | eBioscience | Rat | 1:100 | 14-0081-82 |  |
| **IF** |  |  |  |  |  |
| G9a | Santa Cruz | Mouse |  | sc-515726 |  |
| LC3B | Abcam | Rabbit |  | ab48394 |  |
| ABCB5 | Abcam | Goat |  | ab77549 |  |
| **Secondaries** |  |  |  |  |  |
| Anti-mouse AF 488 | Life Technologies | Donkey |  | A21206 |  |
| Anti-rabbit AF 568 | Life Technologies | Donkey |  | A10042 |  |
| Anti-goat AF 633 | Life Technologies | Donkey |  | A21082 |  |
| Anti-rat AF 647 | Life Technologies | Chicken |  | A21247 |  |

**Supplementary Table S3. Summary of the baseline characteristics of patients in the different datasets.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **TCGA dataset** | **Hugo et al dataset** | **TMA**  |
| **Number of Patients** | 469 | 27 | 40 |
| **Sex** |  |  |  |
|  Male | 289 | 19 | 26 |
|  Female | 180 | 8 | 13 |
|  NA | 0 | 0 | 1 |
| **Age (yrs)** |  |  |  |
|  Median (range) | 58 (48-71) | 61 (19-84) | 69 (32-88) |
| **Tumour Stage** |  |  |  |
|  In situ (stage 0) | 7 |  |  |
|  Low stage (stage I or II) | 235 |  |  |
|  High stage (stage III or IV) | 191 | 27 | 40 |
|  NA | 36 |  |  |
| **Mutation status**  |  |  |  |
|  BRAF | 189 | 14 | 14 |
|  NRAS | 98 | 6 | 8 |
|  NF1  | 47 | 6 |  |

**Supplementary Table S4. Primers used in this study including sequences.**

|  |  |  |
| --- | --- | --- |
| **Primers** | **Use** | **Sequence** |
| ChIP h*MAP1LC3B* F | ChIP | AGGAGATACAAGGGAAGTGGCT |
| ChIP h*MAP1LC3B* R | ChIP | TTGAAGGTCTTCTCCGACGGCAT |
| ChIP h*MAP1LC3B* 5 kb F | ChIP | ATCTTGGCTCACTGCAACCT |
| ChIP h*MAP1LC3B* 5 kb R | ChIP | GTTTGCGTCCTTTCCCTGTA |
| RT h*MAP1LC3B* F | qPCR | GATGTCCGACTTATTCGAGAGC |
| RT h*MAP1LC3B* R | qPCR | TTGAGCTGTAAGCGCCTTCTA |
| RT h*HPRT* F | qPCR | TGCAGACTTTGCTTTCCTTGGTCAGG |
| RT h*HPRT* R | qPCR | CCAACACTTCGTGGGGTCCTTTTCA |
| RT h*CCL2* F | qPCR | GAGAGGCTGAGACTAACCCAGA |
| RT h*CCL2* R | qPCR | ATCACAGCTTCTTTGGGACACT |
| RT h*PTGS2* F | qPCR | GAATGGGGTGATGAGCAGTT |
| RT h*PTGS2* R | qPCR | CAGAAGGGCAGGATACAGC |
| RT h*TNFAIP3* F | qPCR | CGTCCAGGTTCCAGAACACCATTC |
| RT h*TNFAIP3* R | qPCR | TGCGCTGGCTCCTATCTCAGTTG |
| RT h*IRF-1* F | qPCR | GAGGAGGTGAAAGACCAGAGCA |
| RT h*IRF-1* R | qPCR | TAGCATCTCGGCTGGACTTCGA |
| RT h*ICAM1* F | qPCR | GGCCGGCCAGCTTATACAC |
| RT h*ICAM1* R | qPCR | TAGACACTTGAGCTCGGGCA |
| RT h*SOD2* F | qPCR | GGCCTACGTGAACAACCTGAA |
| RT h*SOD2* R | qPCR | CTGTAACATCTCCCTTGGCCA |
| RT h*CD274* F | qPCR | AAATGGAACCTGGCGAAAGC |
| RT h*CD274* R | qPCR | GATGAGCCCCTCAGGCATTT |
| RT m*MAP1LC3B* F | qPCR | GTCCTGGACAAGACCAAGTTCC |
| RT m*MAP1LC3B* R | qPCR | CCATTCACCAGGAGGAAGAAGG |
| RT m*CD274* F | qPCR | GCTCCAAAGGACTTGTACGTG |
| RT m*CD274* R | qPCR | TGATCTGAAGGGCAGCATTTC |
| RT m*IFNG* F | qPCR | CAGCAACAGCAAGGCGAAAAAGG |
| RT m*IFNG* R | qPCR | TTTCCGCTTCCTGAGGCTGGAT |
| RT m*IRF-1* F | qPCR | ATGCCAATCACTCGAATGCG |
| RT m*IRF-1* R | qPCR | TTGTATCGGCCTGTGTGAATG |
| RT m*HPRT* F | qPCR | CACAGGACTAGAACACCTGC |
| RT m*HPRT* R | qPCR | GCTGGTGAAAAGGACCTCT |

**Supplementary Table S5. The expression of *EHMT2* (G9a), *MAP1LC3B* and their combination as independent prognostic indicators.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Covariate** |  **Overall survival** |  | **Relapse-free survival** |
|  **HR**\* | **95%CI**\* |  ***P*** |  |  **HR** | **95%CI** |  ***P*** |
| *EHMT2* (quartiles) | 1.215 | 1.053 - 1.401 | ***0.008*** |  | 1.343 | 1.056 - 1.707 | ***0.0167*** |
| Stage | 1.392 | 1.231 - 1.574 | ***<0.0001*** |  | 1.410 | 1.127 - 1.764 | ***0.0028*** |
| Male vs. Female | 1.136 | 0.816 - 1.582 | 0.4536 |  | 1.419 | 0.802 - 2.509 | 0.2315 |
| BRAF mut vs. WT | 1.447 | 0.717 - 2.918 | 0.3047 |  | 0.925 | 0.187 - 4.569 | 0.9239 |
| NRAS mut vs. WT | 1.472 | 0.736 - 2.944 | 0.2767 |  | 1.002 | 0.200 - 5.038 | 0.9977 |
| NF1 mut vs. WT | 1.484 | 0.815 - 2.702 | 0.1995 |  | 0.407 | 0.085 - 1.956 | 0.2641 |
| WT vs. any mutation | 1.459 | 0.673 - 3.160 | 0.3411 |  | 0.724 | 0.131 - 3.998 | 0.7124 |
|  |  |  |  |  |  |  |  |
|  **Covariate** |  **Overall survival** |  | **Relapse-free survival** |
|  **HR** | **95%CI** |  ***P*** |  |  **HR** | **95%CI** |  ***P*** |
| *MAP1LC3B* (quartiles) | 1.006 | 0.875 - 1.156 | 0.9392 |  | 1.262 | 1.000 - 1.593 | 0.0514 |
| Stage | 1.379 | 1.220 - 1.558 | ***<0.0001*** |  | 1.435 | 1.148 - 1.794 | ***0.0016*** |
| Male vs. Female | 1.113 | 0.799 - 1.551 | 0.5302 |  | 1.416 | 0.801 - 2.503 | 0.2342 |
| BRAF mut vs. WT | 1.424 | 0.701 - 2.892 | 0.3308 |  | 0.983 | 0.198 - 4.881 | 0.9837 |
| NRAS mut vs. WT | 1.636 | 0.815 - 3.282 | 0.1684 |  | 1.354 | 0.272 - 6.731 | 0.7124 |
| NF1 mut vs. WT | 1.524 | 0.838 - 2.770 | 0.1695 |  | 0.522 | 0.110 - 2.471 | 0.4146 |
| WT vs. any mutation | 1.571 | 0.721 - 3.426 | 0.2582 |  | 1.060 | 0.192 - 5.838 | 0.9473 |
|  |  |  |  |  |  |  |  |
|  **Covariate** |  **Overall survival** |  | **Relapse-free survival** |
|  **HR** | **95%CI** |  ***P*** |  |  **HR** | **95%CI** |  ***P*** |
| *EHMT2/MAP1LC3B* | 1.266 | 1.099 - 1.457 | ***0.0011*** |  | 1.286 | 1.018 - 1.625 | ***0.0362*** |
| Stage | 1.365 | 1.208 - 1.542 | ***<0.0001*** |  | 1.368 | 1.091 - 1.715 | ***0.0069*** |
| Male vs. Female | 1.141 | 0.819 - 1.589 | 0.4393 |  | 1.385 | 0.784 - 2.444 | 0.2643 |
| BRAF mut vs. WT | 1.402 | 0.694 - 2.833 | 0.3484 |  | 0.951 | 0.185 - 4.873 | 0.9518 |
| NRAS mut vs. WT | 1.466 | 0.733 - 2.931 | 0.2814 |  | 1.127 | 0.218 - 5.836 | 0.8873 |
| NF1 mut vs. WT | 1.441 | 0.794 - 2.614 | 0.2318 |  | 0.458 | 0.099 - 2.132 | 0.3223 |
| WT vs. any mutation | 1.478 | 0.683 - 3.202 | 0.3241 |  | 0.827 | 0.146 - 4.686 | 0.8309 |
|  |  |  |  |  |  |  |  |

**Supplementary Table S6. Univariate and multivariate survival analysis of LC3B expression in immunotherapy-treated metastatic melanoma.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **1. Survival** |  **Univariate HR (95% CI)** | ***P*** |   | **Multivariate *P*** |
| %LC3B+ cells (>18.5% *vs* ≤18.5%) | 0.1166 (0.0151-0.9040) | ***0.0407*** |  | *0.0763* |
| LC3B intensity (>753.31 *vs* ≤753.31) | 0.3125 (0.0680-1.4365) | *0.137* |  | *0.3154* |
| PDL1 status (pos. *vs* neg.) | 0.2201 (0.0470-1.0311) | ***0.056*** |  | *0.1533* |
| Age (> 65 *vs* ≤ 65) | 0.7421 (0.2277-2.4191) | *0.6226* |  | *0.384* |
| Sex (female *vs* male) | 0.7090 (0.1892-2.6574) | *0.6118* |  | *0.7349* |
| Stage (M1c *vs* others) | 1.5448 (0.3220-7.4107) | *0.5886* |  | *0.8102* |
| LDH (pos. *vs* neg.) | 2.7019 (0.7667-9.5218) | *0.1239* |  | *0.2478* |
| Mutation Status (mut. *vs* WT) | 2.0688 (0.5380-7.9557) | *0.2926* |  | *0.8806* |
| **2. Response (CR/PR)** |  **Univariate HR (95% CI)** | ***P*** |   | **Multivariate *P*** |
| %LC3B+ cells (>18.5% *vs* ≤18.5%) | 0.0925 (0.0121-0.7071) | ***0.0225*** |  | ***0.0228*** |
| LC3B intensity (>753.31 *vs* ≤753.31) | 0.2519 (0.0562-1.1293) | *0.0731* |  | *0.169* |
| PDL1 status (pos. *vs* neg.) | 0.0699 (0.0090-0.5415) | ***0.0113*** |  | ***0.0326*** |
| Age (> 65 *vs* ≤ 65) | 0.4188 (0.1294-1.3555) | *0.1485* |  | *0.5023* |
| Sex (female *vs* male) | 0.5335 (0.1456-1.9552) | *0.3455* |  | *0.3776* |
| Stage (M1c *vs* others) | 1.0033 (0.2655-3.7915) | *0.9962* |  | *0.3306* |
| LDH (pos. *vs* neg.) | 2.0110 (0.6088-6.6432) | *0.2543* |  | *0.5859* |
| Mutation Status (mut. *vs* WT) | 4.9531 (1.0879-22.551) | ***0.0396*** |  | *0.4217* |
| **3. Progression** |  **Univariate HR (95% CI)** | ***P*** |   | **Multivariate *P*** |
| %LC3B+ cells (>18.5% *vs* ≤18.5%) | 0.2836 (0.0941-0.8547) | ***0.0259*** |  | ***0.0502*** |
| LC3B intensity (>753.31 *vs* ≤753.31) | 0.4773 (0.1724-1.3213) | *0.1567* |  | *0.3605* |
| PDL1 status (pos. *vs* neg.) | 0.1794 (0.0512-0.6284) | ***0.0075*** |  | ***0.0195*** |
| Age (> 65 *vs* ≤ 65) | 0.6682 (0.2718-1.6428) | *0.3822* |  | *0.4745* |
| Sex (female *vs* male) | 1.2676 (0.5164-3.1117) | *0.6066* |  | *0.5679* |
| Stage (M1c *vs* others) | 1.7176 (0.4875-6.0520) | *0.4023* |  | *0.8333* |
| LDH (pos. *vs* neg.) | 2.7610 (0.9997-7.6252) | *0.0512* |  | ***0.0523*** |
| Mutation Status (mut. *vs* WT) | 3.7468 (1.2361-11.357) | ***0.0202*** |  | *0.7226* |
| **4. Acquired Resistance** |  **Univariate HR (95% CI)** | ***P*** |   | **Multivariate *P*** |
| %LC3B+ cells (>18.5% *vs* ≤18.5%) | 0.3073 (0.0834-1.1319) | ***0.0776*** |  | *0.9423* |
| LC3B intensity (>753.31 *vs* ≤753.31) | 0.6108 (0.1848-2.0187) | *0.4213* |  | *0.3937* |
| PDL1 status (pos. *vs* neg.) | 0.1794 (0.0512-0.6284) | ***0.0275*** |  | ***0.0376*** |
| Age (> 65 *vs* ≤ 65) | 0.9717 (0.3087-3.0585) | *0.9611* |  | *0.9039* |
| Sex (female *vs* male) | 1.6237 (0.5403-4.8790) | *0.3903* |  | *0.7000* |
| Stage (M1c *vs* others) | 1.5659 (0.3276-7.4836) | *0.5761* |  | *0.6981* |
| LDH (pos. *vs* neg.) | 1.2534 (0.2486-6.3191) | *0.7854* |  | *0.1811* |
| Mutation Status (mut. *vs* WT) | 2.0392 (0.5986-6.9466) | *0.2569* |  | *0.5914* |

**Supplementary Table S7. Gene Set Enrichment Analysis showing the top pathways identified from the D05 RNA-seq expression data.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **GS** | **GS DETAILS** | **SIZE** | **ES** | **NES** | **NOM p-val** | **FDR q-val** | **FWER p-val** | **RANK AT MAX** | **LEADING EDGE** |
| **follow link to MSigDB** |
| 1 | [HALLMARK\_TNFA\_SIGNALING\_VIA\_NFKB](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB) | 40 | 0.7 | 2.21 | 0 | 0 | 0 | 211 | tags=98%, list=33%, signal=137% |
| 2 | [HALLMARK\_INTERFERON\_GAMMA\_ RESPONSE](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_INTERFERON_GAMMA_RESPONSE) | 18 | 0.69 | 2.01 | 0.01 | 0.01 | 0.027 | 65 | tags=50%, list=10%, signal=54% |
| 3 | [HALLMARK\_EPITHELIAL\_MESENCHYMAL\_ TRANSITION](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION) | 15 | 0.7 | 1.94 | 0.01 | 0.02 | 0.064 | 7 | tags=20%, list=1%, signal=20% |
| 4 | [HALLMARK\_MTORC1\_SIGNALING](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING) | 22 | 0.64 | 1.89 | 0.01 | 0.02 | 0.083 | 222 | tags=91%, list=35%, signal=135% |
| 5 | [HALLMARK\_CHOLESTEROL\_HOMEOSTASIS](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_CHOLESTEROL_HOMEOSTASIS) | 19 | 0.64 | 1.84 | 0.02 | 0.03 | 0.122 | 230 | tags=95%, list=36%, signal=144% |
| 6 | [HALLMARK\_UV\_RESPONSE\_UP](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_UV_RESPONSE_UP) | 16 | 0.57 | 1.61 | 0.04 | 0.05 | 0.251 | 196 | tags=69%, list=31%, signal=97% |
| 7 | [HALLMARK\_HYPOXIA](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA) | 16 | 0.52 | 1.45 | 0.07 | 0.08 | 0.421 | 209 | tags=63%, list=33%, signal=91% |
| 8 | [HALLMARK\_P53\_PATHWAY](http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_P53_PATHWAY) | 16 | 0.47 | 1.31 | 0.14 | 0.14 | 0.676 | 211 | tags=56%, list=33%, signal=82% |

GS: Gene set; ES: Enrichment Score; NES: Normalized Enrichment Score; NOM: Nominal; FDR: False-discovery rate; FWER: Familywise error rate.